Pacira BioSciences Inc

NASDAQ:PCRX   3:59:59 PM EDT
59.61
-0.84 (-1.39%)
Products, Regulatory, Earnings Announcements

Pacira Biosciences Announces Top-Line Results From Phase 3 Stride Study

Published: 05/26/2021 12:27 GMT
Pacira BioSciences Inc (PCRX) - Pacira Biosciences Announces Top-line Results From Phase 3 Stride Study Evaluating Exparel As a Lower Extremity Nerve Block.
Pacira Biosciences Inc - Study Did Not Demonstrate Statistical Significance for Primary Endpoint.
Pacira Biosciences - Exparel Achieves Highly Statistically Significant Reductions in Pain, Total Opioid Consumption From 24-96 Hours Versus Bupivacaine Hcl.
Pacira Biosciences Inc - Exparel Hits Statistical Significance for Area Under Curve Cumulative Pain Scores From 12-96 Hours Versus Bupivacaine Hcl.
Pacira Biosciences Inc - Exparel Achieved Statistical Significance Versus Bupivacaine Hcl for Secondary Endpoints.
Pacira Biosciences Inc - Will Complete a Full Analysis of Stride Study.
Pacira Biosciences Inc - Plans to Discuss Data and Next Steps With FDA.
Revenue is expected to be $128.74 Million
Adjusted EPS is expected to be $0.68

Next Quarter Revenue Guidance is expected to be $138.26 Million
Next Quarter EPS Guidance is expected to be $0.79

More details on our Analysts Page.